You are here
- Home
- Therapy Areas
- Respiratory/Inflammation
(OSKIRA-4): A Phase IIB, Multi-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Fostamatinib Disodium Monotherapy Compared With Adalimumab Monotherapy in Patients With Active Rheumatoid Arthritis
- Disease
- rheumatoid arthritis
- Drug Name
- Fostamatinib Disodium
- Generic Name
- Fostamatinib
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- IIb
- Start Date
- Feb 11, 2011
- Study Name
- D4300C00004
- Study Id
- D4300C00004
- ClinicalTrials.gov ID
- NCT01264770
- Recruiting Status
- Open
- Protocol Status
- Not Available
- Report Status
- Not Available
